Its Nestlé Health Science subsidiary, which develops nutritional products to improve health, is pouring money into companies targeting conditions like gut infections, muscle loss, and Alzheimer’s disease. It just opened an outpost in the biotech hub of Kendall Square.
And CEO Greg Behar, who took charge of the subsidiary in 2014 after more than a decade in the pharmaceutical industry, spent three days last week in the Boston area last week, in part to scout biotech companies as investment targets. He said he’s looking for startups with strong management and good science in fields such as brain and gastrointestinal health.
Read Full Article »